Geode Capital Management LLC Buys 107,662 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Geode Capital Management LLC grew its stake in 10x Genomics, Inc. (NASDAQ:TXG) by 11.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 1,009,487 shares of the company’s stock after acquiring an additional 107,662 shares during the period. Geode Capital Management LLC’s holdings in 10x Genomics were worth $197,409,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. increased its position in 10x Genomics by 42.2% during the second quarter. BlackRock Inc. now owns 7,549,175 shares of the company’s stock worth $1,478,280,000 after acquiring an additional 2,242,036 shares during the period. Vanguard Group Inc. increased its position in 10x Genomics by 8.4% during the second quarter. Vanguard Group Inc. now owns 7,079,569 shares of the company’s stock worth $1,386,321,000 after acquiring an additional 551,232 shares during the period. Baillie Gifford & Co. increased its position in 10x Genomics by 260.4% during the second quarter. Baillie Gifford & Co. now owns 5,030,996 shares of the company’s stock worth $985,169,000 after acquiring an additional 3,634,870 shares during the period. ARK Investment Management LLC increased its position in 10x Genomics by 22.7% during the second quarter. ARK Investment Management LLC now owns 4,300,037 shares of the company’s stock worth $842,033,000 after acquiring an additional 795,916 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its position in 10x Genomics by 42.4% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,739,374 shares of the company’s stock worth $340,604,000 after acquiring an additional 518,185 shares during the period. 69.62% of the stock is currently owned by institutional investors.

TXG has been the topic of a number of recent research reports. National Bank Financial initiated coverage on shares of 10x Genomics in a research report on Thursday, September 16th. They set a “sector perform” rating and a $24.00 price target on the stock. Bank of America lowered shares of 10x Genomics from a “buy” rating to a “neutral” rating and set a $180.00 target price on the stock. in a report on Tuesday, September 14th. Citigroup decreased their target price on shares of 10x Genomics from $240.00 to $220.00 and set a “buy” rating on the stock in a report on Thursday, August 5th. Finally, Zacks Investment Research raised shares of 10x Genomics from a “hold” rating to a “buy” rating and set a $161.00 target price on the stock in a report on Thursday, October 7th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, 10x Genomics presently has an average rating of “Buy” and a consensus price target of $173.50.

In related news, Director Sridhar Kosaraju sold 1,500 shares of 10x Genomics stock in a transaction that occurred on Friday, July 23rd. The shares were sold at an average price of $183.67, for a total transaction of $275,505.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 41,666 shares of 10x Genomics stock in a transaction that occurred on Wednesday, September 1st. The stock was sold at an average price of $177.50, for a total transaction of $7,395,715.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 176,181 shares of company stock worth $28,826,407. 11.57% of the stock is currently owned by corporate insiders.

TXG opened at $153.93 on Thursday. The company’s 50 day moving average is $163.00 and its 200-day moving average is $174.82. 10x Genomics, Inc. has a 1-year low of $125.84 and a 1-year high of $208.99. The company has a market cap of $17.07 billion, a P/E ratio of -32.54 and a beta of 1.27.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Tuesday, August 3rd. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.16. 10x Genomics had a negative net margin of 124.24% and a negative return on equity of 8.38%. The company had revenue of $115.84 million for the quarter, compared to the consensus estimate of $112.85 million. During the same period last year, the company posted ($0.41) EPS. The firm’s quarterly revenue was up 170.0% compared to the same quarter last year. On average, equities analysts predict that 10x Genomics, Inc. will post -0.51 earnings per share for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Further Reading: Understanding Relative Strength Index

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXG).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.